Boston ScientificBSX
Recorded

Boston Scientific 2026 Stifel Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration30 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Rick WiseMedTech Analyst

All righty. We're going to get going. Good morning, everybody. Welcome. My name is Rick Wise, Stifel MedTech Analyst, and I'm thrilled to start off today with three outstanding individuals from Boston Scientific. I'd like to welcome and introduce to my left, Lance Bates. Lance is Boston's Executive Vice President and President of, today, Interventional Cardiology and Vascular Therapies, ICVT. Thankfully, on January 1, Lance is going to lead an expanded ICVT, something now to be called Interventional Therapies. I think I'm saying it correctly, Lauren. I'm just glad for the name change, honestly. To Lance's left, Dr. Ken Stein. Ken is Boston's well-known Global Chief Medical Officer, a role he's held since 2023, and since he had the privilege and pleasure of working with my wife at Weill Cornell. I'm very fond of Ken.

Rick WiseMedTech Analyst

Ken's been there since 2009, and he's an electrophysiologist by training, and a distinguished career in medicine. Also joining us is my favorite. I'm not supposed to say that. Head of Investor Relations, Lauren Tengler. Lauren, thank you for being here, and thank you for making this possible today.

Rick WiseMedTech Analyst

Thank you, Rick. I'm going to pick on.

Rick WiseMedTech Analyst

I'm going to start with Lance first. I mean, I warned him. Lance, thank you for doing this. As I look at Boston's portfolio today and reflect on it, as I was thinking about talking to you, I was appreciating that today you're running a, in round numbers, $5 billion business. It's about 25% of today's Boston Scientific, a portfolio that is growing more rapidly than the upper single-digit aspirational goals for the division. This year, it's growing a little more rapidly for a variety of reasons. But once Penumbra closes, that's going to be under your purview as well. So, you might be running. I haven't done careful math. Maybe it's 35% of the total Boston, which I assume will be growing even faster under your excellent leadership.

Rick WiseMedTech Analyst

No pressure. No pressure. Start us off by framing some of the key areas of growth in ICVT today.

Rick WiseMedTech Analyst

Maybe talk about some of the things you'd have us focus on as growth drivers, key growth drivers that you're most excited about.

Lance BatesEVP and President of Interventional Cardiology and Vascular Therapies

Sure. Maybe I'll even take a step back and just frame what you said, like, effective January 1st, what we call Interventional Therapies. That'll include the legacy interventional cardiology business, which would include all the coronary stuff, structural heart, or interventional heart failure business is in that bucket. Then we have our vascular therapies business, which will include the TCAR business, a lot of the things for vascular surgery, plus peripheral procedures, as well as we've put our renal denervation business in our vascular division, just to clarify that. Then the other division that we should potentially talk about even more is our interventional oncology and embolization business. So that's the third division within current Boston Scientific that will be part of Interventional Therapies with Penumbra. When you put all four of those together, you're right, it is a sizable piece.

Lance BatesEVP and President of Interventional Cardiology and Vascular Therapies

There's a couple things maybe to touch on before I get to maybe some of the specific growth drivers, is we're very excited for two macro reasons, is that when you look at the four divisions, the overlap in terms of some of the R&D capabilities is significant. So an example would be from a drug-coated balloon perspective and the pharmacology that goes into that, and the overlap with our IO&E business and some of the things they're doing, like with the TheraSphere business, drug delivery. It's an exciting area that we've got a lot of expertise, and now we can pull them together from an R&D perspective. The other would be from a collaboration with our customers.

Lance BatesEVP and President of Interventional Cardiology and Vascular Therapies

Very specifically, now we are going to have divisions that make a product, but they could be potentially sold across multiple channels that we can pull together under the world of Interventional. Imagine, you have IVL as an example. A vascular surgeon could use it, interventional radiologists could use it in the periphery, interventional cardiologists are going to use it, obviously, in the coronary. That is just one example where there is going to be a product that is going to be used across multiple commercial segments. How we pull all that together to get leverage is going to be pretty exciting. I would say specifically for the growth drivers, it is the breadth of our portfolio.

Lance BatesEVP and President of Interventional Cardiology and Vascular Therapies

Sometimes we talk about that we have a lot of singles and doubles, but when you hit a lot of singles and doubles in a game, meaning, like a $50 million-$100 million a year product or $200 million, those add up to be runs scored in the game. We have built everything around this idea, and I will just use Interventional Cardiology as an example. Everything around the idea of the clinical perspective that the physician goes through, which would be see, prep, and treat. See means you have to see inside the vessel. We have talked about this a lot with our IVUS portfolio. When you see what is happening in the vessel, then you need to decide how you are going to prepare. That is the prep part. What type of calcium treatment or modification tool are you going to use?

Lance BatesEVP and President of Interventional Cardiology and Vascular Therapies

Then actually treat the vessel with one of our drug-eluting therapies. When you put all that together, it is really the breadth and depth of the portfolio that continue to give us reasons to believe that we are going to be accretive growth for Boston Scientific.

Rick WiseMedTech Analyst

That makes a lot of sense. It is a good perspective, and it frames the next question. One of the things that I struggle with as an analyst at times is, just to take peripheral IVL, let us just start there. You are going up against a well-established, excellent competitor in Shockwave, J&J. They have created the market from the ground up. They do not have stents, DCBs, imaging, et cetera. You are talking about owning the whole procedure and every step of the procedure in a different kind of way. But help us think through, talking about the leverage, how do you see your ability to take share in this billion-dollar-plus opportunity? Is it portfolio? Is it this whole procedure concept? How do you win on a head-to-head device comparison?

Lance BatesEVP and President of Interventional Cardiology and Vascular Therapies

Yeah, that's a great question. I'd say first and foremost, the Boston Scientific mantra is we need to be the category leader. You could answer that from the overall procedural perspective. Also, though, we believe we should be the category leader for each component of the procedure. I think it's really important to say we don't want to compete on price. We don't want to compete on bundling things from a contracting perspective. That might be helpful, but we really want to make sure we've got the best clinical technology. Maybe a little bit of history. We developed our internal IVL program years ago. It was probably like 2017, 2018, when we put the engineers in a dark room, said, "Can you figure out maybe potentially a different way to do it?" That's how we came up with this optical laser approach.

Lance BatesEVP and President of Interventional Cardiology and Vascular Therapies

It's very different than Shockwave and some of the other products coming to market. Simple way to explain is some of the electrical systems and current IVL technology is, they've done a great job. First of all, Shockwave has done a great job to really make that work well inside a balloon. I'd say some of the advantages of optical laser technology is it's smaller, it's tinier, it's more miniaturized.

Lance BatesEVP and President of Interventional Cardiology and Vascular Therapies

Think about fiber optics that are smaller diameters than a strand of your hair. We can miniaturize, we can fine-tune this technology. We can do things with it that are going to be very competitive today, but also provide a great roadmap for the future. We want to compete on the technology and the clinical benefit for the technology that we're offering.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day